DPP4 and type 2 diabetes mellitus: Firstly, because some clinical trials on new antidiabetic treatments (e.g., dipeptidyl peptidase-4 inhibitors; DPP-4) have shown to attenuate c-IMT progression compared with conventional treatment in subjects with T2DM and no CVD [21].